Abstract
The clinical treatment of coronary artery disease (CAD) is still restricted to interventions on risk factors, reflected in the administration of statins and antiplatelet. Analyzing the strong proliferative-inflammatory component of the disease, a treatment strategy based on antiproliferative drugs such as those used in cancer treatment, can be a very promising therapeutic route, directed …